LabCorp

CND Life Sciences specializes in developing diagnostic tools for neurodegenerative diseases, particularly focusing on synucleinopathy. The company has introduced the Syn-One Test, which is designed to detect, visualize, and quantify abnormal phosphorylated alpha-synuclein in cutaneous nerve fibers. This commercially available test serves as an objective diagnostic aid for confirming synucleinopathy in patients suspected of having conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure. By providing a convenient and minimally invasive method for diagnosis, CND Life Sciences enhances the ability of medical professionals to accurately identify these complex disorders.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

Percipio Health specializes in utilizing artificial intelligence to provide insights that assist clinicians and caregivers in maintaining a comprehensive understanding of a patient's health. The company has developed a platform that enhances the capabilities of computer vision software, allowing healthcare providers to accurately assess patient health status and identify medications. This technology empowers healthcare professionals to make informed decisions regarding patient care, ultimately improving health outcomes.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

HealthEC, LLC specializes in developing technology solutions for the exchange of healthcare information and management of population health, both in the United States and internationally. The company offers a comprehensive Population Health Management platform that consolidates various elements of care management, including patient attribution, care coordination, and analytics, to serve payers, providers, and employers. Key offerings include "ACO in a Box," which integrates population management and patient engagement functionalities; transformation consulting services; and a Physician Quality Reporting System designed to incentivize quality information reporting. Additionally, HealthEC provides solutions for provider management, claims processing, and extensive analytics to monitor performance and risk. The company, originally founded as IGI Health in 1997, rebranded to HealthEC in 2013 and is headquartered in Edison, New Jersey, with operations extending to Indiana and India. Its client base encompasses hospitals, health systems, physician practices, health plans, and self-insured employers.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that connect diagnosis and treatment through a comprehensive ecosystem of devices, software, and services. By empowering patients to monitor their health and manage diseases, Vital Bio aims to enhance the overall healthcare experience. Their approach seeks to reduce disparities in healthcare outcomes and redistribute control to patients while equipping healthcare providers with the tools necessary to achieve better results.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Getlabs, Inc. is a digital health platform based in Santa Monica, California, that specializes in at-home diagnostics. Founded in 2018, the company facilitates the scheduling of home lab appointments, where mobile phlebotomists visit patients to collect blood samples and other diagnostic tests. These samples are then delivered to laboratories for processing, allowing healthcare organizations to enhance patient care and adherence by providing same-day, nationwide service. Getlabs aims to bridge the gap between virtual and in-person healthcare, thereby improving access to essential diagnostic services. The company has secured $50 million in funding from strategic investors, including major diagnostic laboratories.

PetDx is a San Diego-based molecular diagnostics company focused on enhancing pet health through advanced genomic technologies. The company's primary offering, OncoK9, is a pioneering multi-cancer early detection test that allows veterinarians to identify cancer in dogs through a simple blood draw. This first-in-class liquid biopsy utilizes next-generation sequencing and proprietary bioinformatics to analyze genetic material, facilitating early detection, characterization, and management of cancer in pets. By providing a non-invasive testing option, PetDx supports veterinarians in delivering improved care and outcomes for canine patients.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Ovia Health is a digital healthcare company that provides a comprehensive maternity and family benefits solution aimed at supporting women and families throughout the parenthood journey. Formerly known as Ovuline, the company offers a suite of mobile applications, including Ovia Fertility and Ovia Pregnancy, which deliver personalized information and resources related to fertility, pregnancy, and parenting. By empowering women with customized health insights, Ovia Health enables them to take control of their reproductive health and start families with confidence, ultimately transforming healthcare into a lifestyle choice.

OmniSeq, established in 2015 and headquartered in Buffalo, New York, is a molecular diagnostic laboratory specializing in comprehensive tumor profiling. It provides physicians and patients with actionable genomic information, aiming to match each patient with the most suitable drug or clinical trial. OmniSeq offers New York State CLEP-approved assays, including its flagship 144-gene NGS assay, which covers nearly all known genetic alterations associated with FDA-approved targeted therapies or genotype-directed trials. The company is also dedicated to developing improved diagnostics for immuno-oncology therapy selection, focusing on precision, connectivity, and collaboration to enhance cancer treatment options.

Biospectal is a company focused on remote patient monitoring and biosensing, having developed the OptiBP smartphone app and data platform for blood pressure measurement. This innovative app allows users to measure their blood pressure using the built-in camera of a smartphone, capturing blood flow through the fingertip in a quick and easy manner. The measurement process takes approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal’s proprietary algorithms analyze the optical signals captured by the camera to provide accurate blood pressure readings. Currently, the public beta of the OptiBP app for Android is available in several countries, including the United States, the United Kingdom, France, Germany, Spain, and Switzerland. This technology empowers individuals to monitor their blood pressure anytime and anywhere, transforming smartphones into medical-grade devices without the need for additional peripherals.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, founded in 2012. The company specializes in developing medical products and research tools focused on male fertility management. Its notable offerings include the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a remote blood sampling device for diagnostic testing. Sandstone also manufactures the Trak fertility system, which consists of an engine, a disposable test plate, a sample collection cup, and a dropper, allowing men to monitor their sperm quality and enhance their fertility potential. Additionally, the company provides a mobile application that allows users to track fertility statistics over time, identify potential fertility issues, and take proactive steps to improve their reproductive health. Through these innovations, Sandstone Diagnostics aims to empower individuals to manage their fertility from the comfort of their own homes.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

OmniSeq, established in 2015 and headquartered in Buffalo, New York, is a molecular diagnostic laboratory specializing in comprehensive tumor profiling. It provides physicians and patients with actionable genomic information, aiming to match each patient with the most suitable drug or clinical trial. OmniSeq offers New York State CLEP-approved assays, including its flagship 144-gene NGS assay, which covers nearly all known genetic alterations associated with FDA-approved targeted therapies or genotype-directed trials. The company is also dedicated to developing improved diagnostics for immuno-oncology therapy selection, focusing on precision, connectivity, and collaboration to enhance cancer treatment options.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. The company provides a range of diagnostic services, including cytology and pathology, to healthcare providers and their patients across the United States. Its offerings include testing for human papillomavirus (HPV) using the Digene Hybrid Capture 2 method, as well as tests for gonorrhea and chlamydia. Additionally, ClearPath provides supplemental tissue diagnostics, such as immunohistochemistry and frozen section analysis. The company also specializes in triple testing to identify common vaginitis pathogens and offers Vysis UroVysion testing for non-invasive assessment of bladder cancer. ClearPath Diagnostics analyzes cells from various organs, including breast and thyroid fine needle aspirations and urine specimens. Founded in 1975, it has been operating as a subsidiary of Laboratory Corp. of America Holdings since October 2016.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.

Calif.-based laboratory firm

Ativa Medical Corporation is a medical device manufacturing company focused on developing and commercializing point of care testing diagnostic products tailored for decentralized healthcare settings. Founded in 2008 and headquartered in Saint Paul, Minnesota, the company specializes in providing analyzers that conduct essential hematology and clinical chemistry tests, along with disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. Ativa Medical aims to deliver diagnostic test results in moments rather than hours or days, serving a diverse range of clients, including hospital departments, physician's offices, and remote healthcare clinics across the globe.

Vivify Health Inc. operates a cloud-based, device-agnostic software platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This platform aims to reduce hospital readmissions and associated healthcare costs by enabling virtual interactions between patients and doctors. Vivify Health offers various personal health devices, including tablets, weight scales, and pulse oximeters, to support its remote care management solutions. Founded in 2009 and based in Plano, Texas, the company was formerly known as Intuitive Health, Inc. and rebranded in May 2013. Vivify Health operates as a subsidiary of Optum, Inc., following a transaction announced in December 2019. Through its technology, the company seeks to enhance population health, optimize patient engagement, and improve overall patient satisfaction while facilitating the expansion of physician practice services.

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

MEDTOX Scientific operates a certified drug testing and clinical laboratory that provides a range of forensic and clinical laboratory services. Catering to physician offices, corporations, clinics, health organizations, and government agencies, the company specializes in medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. The laboratory is committed to delivering efficient and effective testing programs while prioritizing excellent customer service and strong client relationships. With a focus on responsiveness and adaptability, MEDTOX ensures that it meets the diverse needs of its clients.

Clearstone Central Laboratories is the largest and most experienced private company.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. provides a range of laboratory testing solutions, specializing in anatomic and molecular pathology services. The company offers diagnostic cytopathology and histopathology, as well as immunohistochemistry services that include a variety of antibodies for biomarker analysis and customized methodologies for processing biopsy specimens. DCL Medical Laboratories also supports clinical trials and delivers reference testing focused on women's health, including ThinPrep Pap test processing, HPV molecular testing, and screening for chlamydia, gonorrhea, and cystic fibrosis carriers. Serving the medical industry across the United States, DCL Medical Laboratories aims to enhance diagnostic accuracy and patient care through its comprehensive testing services.

Monogram Biosciences is a leading developer of innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company specializes in molecular diagnostics and offers products such as Trofile, an assay that determines the tropism of a patient's HIV, facilitating personalized treatment options. Additionally, Monogram provides VeraTag technology, which enhances the development of targeted therapeutics. The company's solutions cater to healthcare providers and pharmaceutical companies, contributing to advancements in precision medicine and improving patient outcomes.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and customer support. The company provides a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to standard laboratory testing, Esoterix offers services tailored for physician specialists and clinical trials. The company also supports its operations with ancillary services, including information technology, managed care, and billing solutions, ensuring a comprehensive approach to laboratory testing and customer service.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Pathology offers a broad array of testing procedures, combining the expertise of an academic-based center with the personal service of a local pathologist. Their services include dermatopathology, gastrointestinal pathology, and uropathology.

ViroMed Laboratories is an FDA-registered laboratory that specializes in infectious disease testing. As a member of LabCorp's Specialty Testing Group, the laboratory provides a range of testing services tailored to support human cells, tissues, and cellular and tissue-based product (HCT/P) donor clients. Its offerings include reproductive donor testing, tissue and eye bank testing, bone marrow and stem cell testing, cord blood testing, and blood testing. ViroMed serves various sectors, including biotechnology, pharmaceuticals, chemicals, medical devices, and integrated healthcare, ensuring that its clients meet regulatory and safety standards in their respective fields.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.